Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Total Current Liabilities (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Total Current Liabilities for 15 consecutive years, with $9.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Current Liabilities rose 32.01% year-over-year to $9.8 million, compared with a TTM value of $9.8 million through Sep 2025, up 32.01%, and an annual FY2024 reading of $6.9 million, down 8.39% over the prior year.
  • Total Current Liabilities was $9.8 million for Q3 2025 at Fennec Pharmaceuticals, up from $8.4 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $9.8 million in Q1 2024 and bottomed at $848000.0 in Q2 2021.
  • Average Total Current Liabilities over 5 years is $5.3 million, with a median of $4.3 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities tumbled 73.42% in 2021, then surged 258.14% in 2022.
  • Year by year, Total Current Liabilities stood at $2.0 million in 2021, then soared by 128.85% to $4.6 million in 2022, then skyrocketed by 63.88% to $7.6 million in 2023, then fell by 8.39% to $6.9 million in 2024, then soared by 41.86% to $9.8 million in 2025.
  • Business Quant data shows Total Current Liabilities for FENC at $9.8 million in Q3 2025, $8.4 million in Q2 2025, and $8.4 million in Q1 2025.